Olit Hookalit E-Cigarettes: Fewer Puffs, More Portability

Nov.07.2024
Olit Hookalit E-Cigarettes: Fewer Puffs, More Portability
E-cigarette brand Olit recently launched the Olit Hookalit X 20000, a disposable, hookah-style e-cigarette with 22ml of 0.35% nicotine liquid. Compared to the previous model, the Olit Hookalit 40000, the new product focuses primarily on portability.

Recently, 2Firsts noted that after the Olit Hookalit 40000, e-cigarette brand Olit has launched another disposable hookah-style e-cigarette, the Olit Hookalit X 20000. According to the distributor website Vapesourcing, the product emphasizes portability and features 22ml of 0.35% nicotine liquid.

 

Olit Hookalit E-Cigarettes: Fewer Puffs, More Portability
Olit Hookalit X 20000|Image source: Olit official website

 

The following table compares the product specifications of the Olit Hookalit X 20000 with the previously released, high-puff e-cigarette product, Olit Hookalit 40000, from the same brand:

 

Olit Hookalit E-Cigarettes: Fewer Puffs, More Portability
Product Parameter Comparison | Illustration: 2Firsts

 

An article on the Ecigator website reviewing the Olit Hookalit 40000 states:

 

"With a nicotine concentration of 0.35%, the Olit Hookalit 40000 is noticeably lower than the 5% concentration commonly found in many other disposable e-cigarettes."

 

"From this perspective, the effect of vaping 40,000 puffs with the Olit Hookalit is roughly equivalent to vaping 2,857 puffs from devices like the SMOK Morf Bar, which have a nicotine concentration of 5%. This means that while the number of puffs may seem impressive, the actual nicotine delivery per puff is much lower."

 

"The large battery and sizable e-liquid tank make this device somewhat bulky compared to other products on the market, resulting in poorer portability."

 

Olit Hookalit E-Cigarettes: Fewer Puffs, More Portability
Olit Hookalit 40000 Review Article | Image source: ecigator

 

The comparison reveals that the new Olit Hookalit X 20000 has a reduced e-liquid capacity and fewer puffs, while its battery capacity has also been lowered accordingly.

 

Additionally, 2Firsts noticed that the Hookalit series of e-cigarettes from the Olit brand, which includes the Olit Hookalit X 20000, Olit Hookalit 40000, and another model, Olit Hookalit Mini, displayed on their official website, all feature a cylindrical shape and do not include the large screen designs that are currently popular on the market.

 

Olit Hookalit E-Cigarettes: Fewer Puffs, More Portability
Olit brand disposable e-cigarette products | Image source: Olit official website

 

 The new Olit Hookalit X 20000, as the "portable" product in the Hookalit series, has already been listed on the official Olit brand website and is available on distributor websites such as Vapesourcing. The product is currently marked as "COMING SOON," with a price of approximately $15.99.

 

It is worth noting that the e-cigarette brand Olit is a subsidiary of Kangor Technology, which has also recently launched a new product, the Kanger SUBOX 50000. This product features an impressive 50,000 puffs and a low nicotine concentration of 0.35%.

 

Olit Hookalit E-Cigarettes: Fewer Puffs, More Portability
Olit Trademark Registration Information | Image source: Tianyancha

 

2Firsts will continue to monitor the latest e-cigarette products and market trends globally, providing the public with accurate and authoritative industry information.

 

2Firsts' product column remains committed to delivering readers the latest product updates in the new tobacco field. We invite readers to submit insights and news on e-cigarette developments.

 

For unique perspectives or information, feel free to contact us at carrie.cai@2firsts.com or scan the QR code below.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22